The disclosure also contemplates the use of one or more of the formulations or compositions, in the manufacture of medicaments for treating, abating, reducing, or ameliorating the symptoms of a disease, dysfunction, or disorder in a mammal, such as a human that has, is suspected of having, or at risk for developing an auris interna disorder
Justin Lathia, PhD: I mean, we're constantly looking for other targets
The substantial weight reduction observed with tirzepatide monotherapy (15-21% body weight in clinical trials) suggests that any perceived benefits likely reflect tirzepatide's pharmacological effects rather than synergistic action
GHK-CU 100mg is the appropriate choice for established research programmes with higher throughput requirements, dose-response studies requiring a range of concentrations, or multi-arm studies comparing this compound against other variables